CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定对CMV免疫的实验测试是否可以确定移植后对这种病毒的免疫力何时存在，以及该测试是否可以预测一个人在移植后免受严重的CMV感染。对于捐赠者来说，这项研究的参与预计将持续大约5天，对于移植接受者来说，将持续1年。一种保护自己免受CMV感染的能力称为CMV特异性细胞免疫。这种免疫力是决定移植后是否会感染严重CMV的最重要因素之一。有多种方法可以衡量这种免疫力。最重要的方法之一是确定你的淋巴细胞(细胞免疫)是否可以杀死感染CMV的细胞。这就是所谓的CTL检测。众所周知，CTL水平良好的人对移植后严重的CMV感染具有保护作用。CTL测试很难进行，已经开发了一种实验测试，试图预测一个人是否具有免疫力。这项实验测试被称为人类白细胞抗原四聚体结合试验(TBA)，尽管已知TBA在试管中工作良好，但它尚未在接受移植的人中进行评估。这项研究的目标是确定如何最好地对移植患者进行TBA测试，并确定您的TBA水平是否可以预测您是否会在移植后免受CMV感染或疾病的保护。这项研究的另一个目标是通过这项实验测试和其他免疫测试来确定您的治疗对您的CMV免疫水平有什么影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether an experimental test for immunity to CMV can determine when immunity to this virus is present after transplantation and whether the test can predict that a person is protected from serious CMV infections after transplantation. Participation in this study is expected to last approximately 5 days for donors, and for 1 year for transplant recipients. An ability to protect yourself from CMV infection is called CMV-specific cellular immunity. This immunity is among the most important factors that determine whether you will get a serious CMV infection after transplantation. There are various ways to measure this immunity. One of the most important ways is to determine if your lymphocytes (cell immunity) can kill CMV-infected cells. This is called a CTL assay. It is known that persons who develop good CTL levels have protection against severe CMV infection after transplantation. The CTL test is difficult to perform and an experimental test has been developed to try to predict whether or not a person is immune. This experimental test is called the HLA-peptide tetramer binding assay (TBA), and, although it is known that the TBA works well in the test tube, it has not yet been evaluated in persons undergoing transplantation. The goals of this study are to determine how best to perform the TBA test for transplant patients and to determine whether or not your TBA levels predict whether you will be protected from CMV infection or disease after transplant. Another goal of this study will be to determine what effects your treatments have on your levels of CMV immunity as measured by this experimental test and other tests of immunity.